Favorable outcome of cancer patients undergoing transcatheter aortic valve replacement

Abstract Aim The aim of this study was to assess the outcome of transcatheter aortic valve replacement (TAVR) in patients with cancer. Methods This is a retrospective study from the nationwide FinnValve registry on 2130 consecutive patients who underwent TAVR for severe AS from January 2008 to October 2017. Results In this cohort, 417 patients (19.6%) had history of cancer and 113 (5.3%) had an active malignancy at the time of TAVR. Patients with any malignancy had similar late mortality than patients without any malignancy (at 7 years, 65.1% vs. 59.3%, adjusted HR 1.105, 95%CI 0.892–1.369). At 7 years, cancer-related mortality was 22.5% among patients with preoperative cancer, and 11.0% in those without preoperative cancer (p  Conclusions This analysis showed that, when properly selected by the heart team and oncologists, most cancer patients undergoing TAVR can achieve a good survival and eventually die of other diseases. Blood malignancies seem to carry a poor prognosis in these patients. Clinical trial registration: ClinicalTrials.gov Identifier: NCT03385915 ; https://clinicaltrials.gov/ct2/show/NCT03385915 .